You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

~ Buy the INGREZZA (valbenazine tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

INGREZZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ingrezza, and when can generic versions of Ingrezza launch?

Ingrezza is a drug marketed by Neurocrine and is included in one NDA. There are twenty-two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and three patent family members in thirty-three countries.

The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.

DrugPatentWatch® Generic Entry Outlook for Ingrezza

Ingrezza was eligible for patent challenges on April 11, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 18, 2038. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (valbenazine tosylate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for INGREZZA
Drug Prices for INGREZZA

See drug prices for INGREZZA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INGREZZA
Generic Entry Date for INGREZZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INGREZZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Michael BlochPhase 2
The Orthopedic FoundationPhase 4
Neurocrine BiosciencesPhase 2

See all INGREZZA clinical trials

Pharmacology for INGREZZA
Paragraph IV (Patent) Challenges for INGREZZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INGREZZA Capsules valbenazine tosylate 60 mg 209241 1 2022-02-14
INGREZZA Capsules valbenazine tosylate 40 mg and 80 mg 209241 4 2021-04-12

US Patents and Regulatory Information for INGREZZA

INGREZZA is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of INGREZZA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting INGREZZA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Valbenazine salts and polymorphs thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER

Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

High dosage valbenazine formulation and compositions, methods, and kits related thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

High dosage valbenazine formulation and compositions, methods, and kits related thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

Methods for the administration of certain VMAT2 inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

High dosage valbenazine formulation and compositions, methods, and kits related thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

High dosage valbenazine formulation and compositions, methods, and kits related thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquin- olin-2-ol compounds and methods relating thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquin- olin-2-ol compounds and methods relating thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD OF TREATING HUNTINGTON'S CHOREA

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquin- olin-2-ol compounds and methods relating thereto
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TARDIVE DYSKINESIA

FDA Regulatory Exclusivity protecting INGREZZA

FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
Exclusivity Expiration: ⤷  Try a Trial

TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for INGREZZA

When does loss-of-exclusivity occur for INGREZZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2819
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 18335259
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2020005373
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 76000
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1372567
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 2090809
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 84333
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 3300
Estimated Expiration: ⤷  Try a Trial

Patent: 1770
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 50006
Estimated Expiration: ⤷  Try a Trial

Patent: 20534305
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 20002841
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 175
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 1919622
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INGREZZA around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 202090932 СПОСОБЫ ВВЕДЕНИЯ НЕКОТОРЫХ VMAT2-ИНГИБИТОРОВ ⤷  Try a Trial
Eurasian Patent Organization 201890852 СОЛИ ВАЛБЕНАЗИНА И ИХ ПОЛИМОРФЫ ⤷  Try a Trial
Mexico 2022000559 METODOS PARA LA ADMINISTRACION DE CIERTOS INHIBIDORES DE VMAT2 A PACIENTES CON INSUFICIENCIA RENAL GRAVE. (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS TO PATIENTS WITH SEVERE RENAL IMPAIRMENT.) ⤷  Try a Trial
Canada 3051834 PROCEDES D'ADMINISTRATION DE CERTAINS INHIBITEURS DE VMAT2 (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing